# | Title | Journal | Year | Citations |
---|
1 | Pediatric modification of the Montreal classification for inflammatory bowel disease | Inflammatory Bowel Diseases | 2011 | 1,182 |
2 | Long-Term Evolution of Disease Behavior of Crohn's Disease | Inflammatory Bowel Diseases | 2002 | 1,164 |
3 | Low counts of Faecalibacterium prausnitzii in colitis microbiota | Inflammatory Bowel Diseases | 2009 | 1,052 |
4 | Epidemiology of pediatric inflammatory bowel disease: A systematic review of international trends | Inflammatory Bowel Diseases | 2011 | 779 |
5 | Inflammatory bowel disease: Epidemiology, pathogenesis, and therapeutic opportunities | Inflammatory Bowel Diseases | 2006 | 756 |
6 | Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease | Inflammatory Bowel Diseases | 2012 | 662 |
7 | Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative Colitis | Inflammatory Bowel Diseases | 2008 | 645 |
8 | Distinct Cytokine Patterns Identified from Multiplex Profiles of Murine DSS and TNBS-Induced Colitis | Inflammatory Bowel Diseases | 2009 | 611 |
9 | Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohnʼs disease | Inflammatory Bowel Diseases | 2009 | 584 |
10 | Extraintestinal Manifestations of Inflammatory Bowel Disease | Inflammatory Bowel Diseases | 2015 | 565 |
11 | Current Understanding of Dysbiosis in Disease in Human and Animal Models | Inflammatory Bowel Diseases | 2016 | 555 |
12 | Update on the incidence and prevalence of Crohnʼs disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000 | Inflammatory Bowel Diseases | 2007 | 549 |
13 | Consensus Conference: Colorectal Cancer Screening and Surveillance in Inflammatory Bowel Disease | Inflammatory Bowel Diseases | 2005 | 530 |
14 | Intestinal barrier dysfunction in inflammatory bowel diseases | Inflammatory Bowel Diseases | 2009 | 506 |
15 | Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases | Inflammatory Bowel Diseases | 2011 | 505 |
16 | Development of the Crohnʼs disease digestive damage score, the Lémann score | Inflammatory Bowel Diseases | 2011 | 496 |
17 | Correlation of C-Reactive Protein With Clinical, Endoscopic, Histologic, and Radiographic Activity in Inflammatory Bowel Disease | Inflammatory Bowel Diseases | 2005 | 488 |
18 | Depression and anxiety in inflammatory bowel disease: A review of comorbidity and management | Inflammatory Bowel Diseases | 2009 | 480 |
19 | Importance of disrupted intestinal barrier in inflammatory bowel diseases | Inflammatory Bowel Diseases | 2011 | 466 |
20 | Mechanisms of action of probiotics: Recent advances | Inflammatory Bowel Diseases | 2009 | 448 |
21 | Invasive potential of gut mucosa-derived fusobacterium nucleatum positively correlates with IBD status of the host | Inflammatory Bowel Diseases | 2011 | 437 |
22 | Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986–2005: A KASID study | Inflammatory Bowel Diseases | 2008 | 427 |
23 | Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor α agents | Inflammatory Bowel Diseases | 2007 | 423 |
24 | Magnetic resonance imaging for evaluation of Crohnʼs disease | Inflammatory Bowel Diseases | 2011 | 413 |
25 | Critical role of IL-17 receptor signaling in acute TNBS-induced colitis | Inflammatory Bowel Diseases | 2006 | 411 |
26 | Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohnʼs disease | Inflammatory Bowel Diseases | 2009 | 407 |
27 | Controversies Revisited | Inflammatory Bowel Diseases | 2016 | 405 |
28 | C-Reactive Protein as a Marker for Inflammatory Bowel Disease | Inflammatory Bowel Diseases | 2004 | 400 |
29 | Crohnʼs disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohnʼs disease activity index and endoscopic findings | Inflammatory Bowel Diseases | 2008 | 397 |
30 | World Gastroenterology Organization Practice Guidelines for the Diagnosis and Management of IBD in 2010 | Inflammatory Bowel Diseases | 2010 | 393 |
31 | Declining Risk of Colorectal Cancer in Inflammatory Bowel Disease | Inflammatory Bowel Diseases | 2013 | 391 |
32 | Infliximab in the Treatment of Severe, Steroid-Refractory Ulcerative Colitis: A Pilot Study | Inflammatory Bowel Diseases | 2001 | 377 |
33 | Th1/Th2 Cells | Inflammatory Bowel Diseases | 1999 | 373 |
34 | Specificities of the fecal microbiota in inflammatory bowel disease | Inflammatory Bowel Diseases | 2006 | 373 |
35 | Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases# | Inflammatory Bowel Diseases | 2007 | 373 |
36 | Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease | Inflammatory Bowel Diseases | 2006 | 371 |
37 | NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis | Inflammatory Bowel Diseases | 2011 | 366 |
38 | Antitumor Necrosis Factor Therapy for Inflammatory Bowel Disease: A Review of Agents, Pharmacology, Clinical Results, and Safety | Inflammatory Bowel Diseases | 1999 | 356 |
39 | Changes in Clinical Characteristics, Course, and Prognosis of Inflammatory Bowel Disease during the Last 5 Decades: A Population-Based Study from Copenhagen, Denmark | Inflammatory Bowel Diseases | 2007 | 340 |
40 | Molecular diversity of Escherichia coli in the human gut: New ecological evidence supporting the role of adherent-invasive E. coli (AIEC) in Crohnʼs disease | Inflammatory Bowel Diseases | 2009 | 339 |
41 | Dietary Risk Factors for Inflammatory Bowel Disease | Inflammatory Bowel Diseases | 2005 | 338 |
42 | Il-6 signaling in inflammatory bowel disease: Pathophysiological role and clinical relevance | Inflammatory Bowel Diseases | 2007 | 336 |
43 | Lactobacillus plantarum 299V in the Treatment and Prevention of Spontaneous Colitis in Interleukin-10-Deficient Mice | Inflammatory Bowel Diseases | 2002 | 325 |
44 | Effect of Probiotics on Inducing Remission and Maintaining Therapy in Ulcerative Colitis, Crohnʼs Disease, and Pouchitis | Inflammatory Bowel Diseases | 2014 | 320 |
45 | Dysbiosis of fecal microbiota in Crohnʼs disease patients as revealed by a custom phylogenetic microarray | Inflammatory Bowel Diseases | 2010 | 314 |
46 | A Randomized, Double-blind Trial of Lactobacillus GG Versus Placebo in Addition to Standard Maintenance Therapy for Children with Crohnʼs Disease | Inflammatory Bowel Diseases | 2005 | 303 |
47 | A Randomized Clinical Trial of Ciprofloxacin and Metronidazole to Treat Acute Pouchitis | Inflammatory Bowel Diseases | 2001 | 300 |
48 | Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): Upregulated colonic IL-17F expression in active Crohnʼs disease and analysis of the IL17F p.His161Arg polymorphism in IBD | Inflammatory Bowel Diseases | 2008 | 291 |
49 | Both IL-12p70 and IL-23 are synthesized during active Crohnʼs disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody | Inflammatory Bowel Diseases | 2006 | 290 |
50 | Intestinal Inflammation and Mucosal Barrier Function | Inflammatory Bowel Diseases | 2014 | 287 |